Epiretinal brachytherapy for wet AMD gets NICE thumbs down
This article was originally published in Clinica
Executive Summary
Epiretinal brachytherapy for treating wet age-related macular degeneration (AMD) should only be used in the context of research, the UK’s National Institute for Health and Clinical Excellence (NICE) has said. In guidance issued today under its interventional procedures programme, NICE cited safety concerns raised by the technique and the need for better evidence on its effectiveness.